Synergy between Th1 and Th2 responses during Mycobacterium tuberculosis infection: A review of current understanding

被引:47
作者
Abebe, Fekadu [1 ]
机构
[1] Univ Oslo, Fac Med, Inst Hlth & Soc, 1130 Blindern, N-0318 Oslo, Norway
关键词
Tuberculosis; antibody; cell-mediated; immunity; synergy; HEPARIN-BINDING HEMAGGLUTININ; CELL-MEDIATED-IMMUNITY; T-CELL; PROTECTIVE IMMUNITY; LATENT TUBERCULOSIS; ANTIBODY-RESPONSES; INTERFERON-GAMMA; FC-RECEPTORS; IFN-GAMMA; VACCINE;
D O I
10.1080/08830185.2019.1632842
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Induction of Th1 (cell-mediated) immunity and associated production of IFN-gamma by CD4+ T cells has been widely used as a marker of protective immunity against tuberculosis (TB). This is based on two assumptions. The first is the widely accepted view that Mycobacterium tuberculosis (Mtb), the causative agent of TB is an obligate intracellular pathogen, and the second is based on the Th1/Th2 paradigm, which posits that polarization of CD4+ T cells into type1 (cell-mediated) and type 2 (humoral) is central for proper induction of protective immunity against pathogens. However, almost all licensed vaccines currently in use are primarily anti-body based whether intracellular or extra-cellular. In addition, converging data from both animal models and humans indicate that the production of IFN-gamma alone is not sufficient to confer protection against TB. In addition, a substantial body of the literature suggests that, in addition to Th1 cells, antibody classes and sub-classes are protective against TB. In a recent study, we have shown that there is a synergy between IFN-gamma (cell-mediated) and IgA (humoral) in human population in an endemic setting. In this review, current data from both animal and human studies that support mixed Th1 and Th2 responses that are protective against Mtb and other pathogens are presented.
引用
收藏
页码:172 / 179
页数:8
相关论文
共 81 条
[1]   Association of ESAT-6/CFP-10-induced IFN-, TNF- and IL-10 with clinical tuberculosis: evidence from cohorts of pulmonary tuberculosis patients, household contacts and community controls in an endemic setting [J].
Abebe, F. ;
Belay, M. ;
Legesse, M. ;
Mihret, A. ;
Franken, K. S. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2017, 189 (02) :241-249
[2]   The protective role of antibody responses during Mycobacterium tuberculosis infection [J].
Abebe, F. ;
Bjune, G. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 157 (02) :235-243
[3]   Intraperitoneal immunization with Urease loaded N-trimethyl Chitosan nanoparticles elicits high protection against Brucella melitensis and Brucella abortus infections [J].
Abkar, Morteza ;
Fasihi-Ramandi, Mandi ;
Kooshki, Hamid ;
Lotfi, Abbas Sahebghadam .
IMMUNOLOGY LETTERS, 2018, 199 :53-60
[4]   Monoclonal antibody therapy of cancer [J].
Adams, GP ;
Weiner, LM .
NATURE BIOTECHNOLOGY, 2005, 23 (09) :1147-1157
[5]   Adjuvant modulation of the cytokine balance in Mycobacterium tuberculosis subunit vaccines;: immunity, pathology and protection [J].
Agger, Else Marie ;
Cassidy, Joseph P. ;
Brady, Joseph ;
Korsholm, Karen S. ;
Vingsbo-Lundberg, Carina ;
Andersen, Peter .
IMMUNOLOGY, 2008, 124 (02) :175-185
[6]   Restoration of mycobacterial antigen-induced proliferation and interferon-γ responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy [J].
Al-Attiyah, R ;
Mustafa, AS ;
Abal, AT ;
Madi, NM ;
Andersen, P .
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2003, 38 (03) :249-256
[7]   The era of the immunoglobulin A Fc receptor FcRI; its function and potential as target in disease [J].
Aleyd, Esil ;
Heineke, Marieke H. ;
van Egmond, Marjolein .
IMMUNOLOGICAL REVIEWS, 2015, 268 (01) :123-138
[8]  
Anchkar JM, 2015, IMMUNOL REV, V264, P167, DOI DOI 10.1111/IMR.12276
[9]  
BACHMANN MF, 1994, MED MICROBIOL IMMUN, V183, P315
[10]   FORMALIN INACTIVATION OF VESICULAR STOMATITIS-VIRUS IMPAIRS T-CELL- BUT NOT T-HELP-INDEPENDENT B-CELL RESPONSES [J].
BACHMANN, MF ;
KUNDIG, TM ;
KALBERER, CP ;
HENGARTNER, H ;
ZINKERNAGEL, RM .
JOURNAL OF VIROLOGY, 1993, 67 (07) :3917-3922